Supervisor Database Search
Guidance for ICAT Supervisors
The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year.
You can read about the ICAT supervisor selection process and eligibility criteria below:
Terms of reference/guide to supervising ICAT Fellows.
You can read the terms of reference for supervisors actively supervising ICAT Fellows below:
Supervisor Database
Search for supervisors below. You can filter your search using the options and select multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.
Full NameProfessor Manuel Salto-Tellez
Northern Ireland Molecular Pathology Laboratory
Queen's University Belfast
Webpage:qub.ac.uk
Email hidden; Javascript is required.
- genetics, genomics and molecular biology
- cancer/oncology
- Pathology
- Oncology
I am a histopathologist and a molecular diagnostician. Over the last 15 years, the focus of my translational research and my diagnostic work has been to marry phenotype and genotype. Using molecular pathology approaches, I have described the clinical significance of stem cell markers such as CD133 [Mod Pathol. 2010 Mar;23(3):450-7] and SALL4 [N Engl J Med. 2013 Jun 13;368(24):2266 -76] in hepatocellular carcinoma (HCC). My laboratory generated the first evidence that the SALL4 protein, usually involved in cancer stem cell biology, was upregulated in HCC and had a strong negative prognostic value. This work went on to characterize a peptide that would inhibit the growth of HCC in a mouse model, validating SALL4 as a therapeutic target.
In general, my laboratories has contributed to understanding the clinical relevance of approximately 20 candidate biomarkers and disease mediators such as EphA2 (Clin Can Res 2015), TBX2 (Oncotarget 2014), CD44-v8 10 (Can Res 2014), Hydrogen Sulphide [FASEB J. 2005 Jul;19(9):1196-8.], FGFR4 (Cell Death Dis 2014), cell adhesion and chromatin remodeling genes [Nat Genet. 2012 May;44(5):570-4] and AXL (Clin Can Res 2014), representing one of the main efforts by a molecular pathologist, world-wide, in defining the clinical relevance of cancer biomarkers.